These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38428305)

  • 1. Distinct binding modes of a benzothiazole derivative confer structural bases for increasing ERK2 or p38α MAPK selectivity.
    Hasegawa S; Yoshida M; Nagao H; Sugiyama H; Sawa M; Kinoshita T
    Biochem Biophys Res Commun; 2024 Apr; 704():149707. PubMed ID: 38428305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low entropic cost of binding confers high selectivity on an allosteric ERK2 inhibitor.
    Sugiyama H; Yoshida M; Nagao H; Sawa M; Kinoshita T
    Bioorg Med Chem Lett; 2023 Sep; 93():129431. PubMed ID: 37544371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitogen-activated protein kinase (MAPK) phosphatase 3-mediated cross-talk between MAPKs ERK2 and p38alpha.
    Zhang YY; Wu JW; Wang ZX
    J Biol Chem; 2011 May; 286(18):16150-62. PubMed ID: 21454500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of a cysteine residue in the active site of ERK and the MAPKK family.
    Ohori M; Kinoshita T; Yoshimura S; Warizaya M; Nakajima H; Miyake H
    Biochem Biophys Res Commun; 2007 Feb; 353(3):633-7. PubMed ID: 17194451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct binding determinants for ERK2/p38alpha and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1.
    Slack DN; Seternes OM; Gabrielsen M; Keyse SM
    J Biol Chem; 2001 May; 276(19):16491-500. PubMed ID: 11278799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linear motif specificity in signaling through p38α and ERK2 mitogen-activated protein kinases.
    Torres Robles J; Lou HJ; Shi G; Pan PL; Turk BE
    Proc Natl Acad Sci U S A; 2023 Nov; 120(48):e2316599120. PubMed ID: 37988460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking sites on mitogen-activated protein kinase (MAPK) kinases, MAPK phosphatases and the Elk-1 transcription factor compete for MAPK binding and are crucial for enzymic activity.
    Bardwell AJ; Abdollahi M; Bardwell L
    Biochem J; 2003 Mar; 370(Pt 3):1077-85. PubMed ID: 12529172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selectivity of docking sites in MAPK kinases.
    Bardwell AJ; Frankson E; Bardwell L
    J Biol Chem; 2009 May; 284(19):13165-73. PubMed ID: 19196711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DEF pocket in p38α facilitates substrate selectivity and mediates autophosphorylation.
    Tzarum N; Komornik N; Ben Chetrit D; Engelberg D; Livnah O
    J Biol Chem; 2013 Jul; 288(27):19537-47. PubMed ID: 23671282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into the catalytic activation of the MAPK phosphatase PAC-1 induced by its substrate MAPK ERK2 binding.
    Zhang Q; Muller M; Chen CH; Zeng L; Farooq A; Zhou MM
    J Mol Biol; 2005 Dec; 354(4):777-88. PubMed ID: 16288922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrogen-exchange mass spectrometry reveals activation-induced changes in the conformational mobility of p38alpha MAP kinase.
    Sours KM; Kwok SC; Rachidi T; Lee T; Ring A; Hoofnagle AN; Resing KA; Ahn NG
    J Mol Biol; 2008 Jun; 379(5):1075-93. PubMed ID: 18501927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A distinct interaction mode revealed by the crystal structure of the kinase p38α with the MAPK binding domain of the phosphatase MKP5.
    Zhang YY; Wu JW; Wang ZX
    Sci Signal; 2011 Dec; 4(204):ra88. PubMed ID: 22375048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modeling of p38α mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations.
    Chang HW; Chung FS; Yang CN
    J Chem Inf Model; 2013 Jul; 53(7):1775-86. PubMed ID: 23808966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of kinase-interaction-motif protein tyrosine phosphatases with the mitogen-activated protein kinase ERK2.
    Francis DM; Koveal D; Tortajada A; Page R; Peti W
    PLoS One; 2014; 9(3):e91934. PubMed ID: 24637728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
    Suplatov D; Kopylov K; Sharapova Y; Švedas V
    J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.
    Astolfi A; Iraci N; Manfroni G; Barreca ML; Cecchetti V
    ChemMedChem; 2015 Jun; 10(6):957-69. PubMed ID: 26012502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular signal-regulated kinase 2 (ERK2) phosphorylation sites and docking domain on the nuclear pore complex protein Tpr cooperatively regulate ERK2-Tpr interaction.
    Vomastek T; Iwanicki MP; Burack WR; Tiwari D; Kumar D; Parsons JT; Weber MJ; Nandicoori VK
    Mol Cell Biol; 2008 Nov; 28(22):6954-66. PubMed ID: 18794356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.
    Astolfi A; Iraci N; Sabatini S; Barreca ML; Cecchetti V
    Molecules; 2015 Aug; 20(9):15842-61. PubMed ID: 26334265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Novel Inhibitory Allosteric Site in p38α.
    Gomez-Gutierrez P; Campos PM; Vega M; Perez JJ
    PLoS One; 2016; 11(11):e0167379. PubMed ID: 27898710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of inhibitor selectivity in MAP kinases.
    Wang Z; Canagarajah BJ; Boehm JC; Kassisà S; Cobb MH; Young PR; Abdel-Meguid S; Adams JL; Goldsmith EJ
    Structure; 1998 Sep; 6(9):1117-28. PubMed ID: 9753691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.